(ELV) Elevance Health - Overview
Stock: Health Insurance, Pharmacy Services, Specialty Care, Administrative Services
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.95% |
| Yield on Cost 5y | 2.50% |
| Yield CAGR 5y | 10.91% |
| Payout Consistency | 100.0% |
| Payout Ratio | 22.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 42.8% |
| Relative Tail Risk | -7.84% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.22 |
| Alpha | -19.02 |
| Character TTM | |
|---|---|
| Beta | 0.180 |
| Beta Downside | 0.212 |
| Drawdowns 3y | |
|---|---|
| Max DD | 50.38% |
| CAGR/Max DD | -0.18 |
Description: ELV Elevance Health January 29, 2026
Elevance Health Inc. (NYSE: ELV) is a U.S. health-benefits company organized into four operating segments-Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It delivers a full spectrum of health plans (individual, employer-group, Medicare, Medicaid, and Federal Employee Program) and ancillary products such as stop-loss, dental, vision, and supplemental insurance, while also operating a large pharmacy-services business that includes home-delivery, specialty pharmacy, formulary management, and infusion services. The firm’s technology platform, HealthOS, supports utilization management, virtual care, payment-integrity, data analytics, and post-acute care coordination, and its brands include Anthem Blue Cross & Blue Shield, Wellpoint, and Carelon.
Key recent metrics (Q4 2024 / FY 2024):
• Total revenue ≈ $152 billion, up 5 % YoY, driven by a 7 % rise in pharmacy-services revenue and continued growth in Medicare Advantage enrollment (≈ 6 % YoY).
• Membership base ≈ 115 million lives, with employer-group coverage stable and Medicaid enrollment expanding in several states following recent policy extensions.
• Adjusted EPS $4.85, net income $1.2 billion, with an operating margin of 4.5 % after integrating the Carelon acquisitions.
Sector drivers include an aging U.S. population (projected 10 % increase in Medicare-eligible adults by 2030), sustained inflation in medical-service prices (≈ 4 % annual CPI for health care), and consolidation trends in the pharmacy-benefit-management market that favor large, integrated insurers.
For a deeper, data-rich dive into Elevance’s valuation dynamics, you may find ValueRay’s analytical tools worth exploring.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 5.53b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 2.32 > 1.0 |
| NWC/Revenue: 11.75% < 20% (prev 7.58%; Δ 4.18% < -1%) |
| CFO/TA 0.04 > 3% & CFO 4.91b > Net Income 5.53b |
| Net Debt (23.39b) to EBITDA (10.02b): 2.34 < 3 |
| Current Ratio: 1.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (225.8m) vs 12m ago -3.13% < -2% |
| Gross Margin: 50.46% > 18% (prev 0.28%; Δ 5018 % > 0.5%) |
| Asset Turnover: 162.8% > 50% (prev 149.3%; Δ 13.51% > 0%) |
| Interest Coverage Ratio: 6.16 > 6 (EBITDA TTM 10.02b / Interest Expense TTM 1.38b) |
Altman Z'' 3.11
| A: 0.19 (Total Current Assets 63.78b - Total Current Liabilities 40.88b) / Total Assets 122.75b |
| B: 0.29 (Retained Earnings 35.59b / Total Assets 122.75b) |
| C: 0.07 (EBIT TTM 8.48b / Avg Total Assets 119.64b) |
| D: 0.45 (Book Value of Equity 35.05b / Total Liabilities 78.67b) |
| Altman-Z'' Score: 3.11 = A |
Beneish M -3.32
| DSRI: 1.08 (Receivables 22.35b/18.40b, Revenue 194.82b/174.01b) |
| GMI: 0.55 (GM 50.46% / 27.94%) |
| AQI: 0.91 (AQ_t 0.44 / AQ_t-1 0.49) |
| SGI: 1.12 (Revenue 194.82b / 174.01b) |
| TATA: 0.01 (NI 5.53b - CFO 4.91b) / TA 122.75b) |
| Beneish M-Score: -3.32 (Cap -4..+1) = AA |
What is the price of ELV shares?
Over the past week, the price has changed by -6.79%, over one month by -0.40%, over three months by +3.69% and over the past year by -11.64%.
Is ELV a buy, sell or hold?
- StrongBuy: 13
- Buy: 5
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ELV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 395.4 | 14% |
| Analysts Target Price | 395.4 | 14% |
| ValueRay Target Price | 349.3 | 0.7% |
ELV Fundamental Data Overview January 24, 2026
P/E Forward = 13.089
P/S = 0.4302
P/B = 1.8702
P/EG = 1.0732
Revenue TTM = 194.82b USD
EBIT TTM = 8.48b USD
EBITDA TTM = 10.02b USD
Long Term Debt = 31.17b USD (from longTermDebt, last quarter)
Short Term Debt = 929.0m USD (from shortTermDebt, last quarter)
Debt = 32.10b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 23.39b USD (from netDebt column, last quarter)
Enterprise Value = 107.21b USD (83.82b + Debt 32.10b - CCE 8.71b)
Interest Coverage Ratio = 6.16 (Ebit TTM 8.48b / Interest Expense TTM 1.38b)
EV/FCF = 28.46x (Enterprise Value 107.21b / FCF TTM 3.77b)
FCF Yield = 3.51% (FCF TTM 3.77b / Enterprise Value 107.21b)
FCF Margin = 1.93% (FCF TTM 3.77b / Revenue TTM 194.82b)
Net Margin = 2.84% (Net Income TTM 5.53b / Revenue TTM 194.82b)
Gross Margin = 50.46% ((Revenue TTM 194.82b - Cost of Revenue TTM 96.51b) / Revenue TTM)
Gross Margin QoQ = 14.18% (prev 15.62%)
Tobins Q-Ratio = 0.87 (Enterprise Value 107.21b / Total Assets 122.75b)
Interest Expense / Debt = 1.09% (Interest Expense 351.0m / Debt 32.10b)
Taxrate = 15.58% (219.0m / 1.41b)
NOPAT = 7.16b (EBIT 8.48b * (1 - 15.58%))
Current Ratio = 1.56 (Total Current Assets 63.78b / Total Current Liabilities 40.88b)
Debt / Equity = 0.73 (Debt 32.10b / totalStockholderEquity, last quarter 43.95b)
Debt / EBITDA = 2.34 (Net Debt 23.39b / EBITDA 10.02b)
Debt / FCF = 6.21 (Net Debt 23.39b / FCF TTM 3.77b)
Total Stockholder Equity = 42.87b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.62% (Net Income 5.53b / Total Assets 122.75b)
RoE = 12.91% (Net Income TTM 5.53b / Total Stockholder Equity 42.87b)
RoCE = 11.45% (EBIT 8.48b / Capital Employed (Equity 42.87b + L.T.Debt 31.17b))
RoIC = 9.70% (NOPAT 7.16b / Invested Capital 73.75b)
WACC = 5.01% (E(83.82b)/V(115.92b) * Re(6.58%) + D(32.10b)/V(115.92b) * Rd(1.09%) * (1-Tc(0.16)))
Discount Rate = 6.58% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.14%
[DCF Debug] Terminal Value 86.08% ; FCFF base≈2.61b ; Y1≈2.54b ; Y5≈2.56b
Fair Price DCF = 239.5 (EV 76.62b - Net Debt 23.39b = Equity 53.23b / Shares 222.2m; r=5.90% [WACC]; 5y FCF grow -3.53% → 2.90% )
EPS Correlation: 8.29 | EPS CAGR: 4.35% | SUE: 1.95 | # QB: 1
Revenue Correlation: 95.77 | Revenue CAGR: 10.49% | SUE: 1.33 | # QB: 5
EPS next Quarter (2026-03-31): EPS=10.30 | Chg30d=-0.130 | Revisions Net=-4 | Analysts=16
EPS next Year (2026-12-31): EPS=26.82 | Chg30d=-0.123 | Revisions Net=-3 | Growth EPS=-10.5% | Growth Revenue=+2.9%